Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — AusBiotech Conference November 2019
15 slides from Prescient Therapeutics's conference presentation, Oct 31, 2019
Slide 1: What is all this current fuss about "Ras"?
WHAT IS ALL THIS CURRENT FUSS ABOUT “RAS”? Prescient Therapeutics Limited (ASX: PTX) AusBiotech Conference November 2019
Slide 2: Disclaimer and safe harbor
Disclaimer and safe harbor Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on
Slide 3: Corporate Snapshot
Corporate Snapshot KEY METRICS ASX Ticker PTX Share Price1 A$0.061 Market Capitalisation1 A$24 M Total Issued Capital 394.3 M shares Cash Position2 A$8.7 M 95.4M listed PTXOC; Options 12.1M unlisted Top 20 Own 50% 6 MONTH SHARE PRICE PERFORMANCE Institutions 36% Retail 60% Directors 4% RESEARCH HC W
Slide 4: Prescient's approach: address the mutations causing cancer
Prescient’s approach: address the mutations causing cancer Cells divide over Sometimes and over mistakes are made MUTATIONS CANCER 4 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 5: Why are we hearing about Ras mutations all of a sudden?
Why are we hearing about Ras mutations all of a sudden? …and just yesterday: …and this morning:
Slide 6: What are Ras mutations?
What are Ras mutations? • The first human oncogene (cancer-causing) • Switch stuck “on” causing uncontrolled discovered in 1982 growth • Remains the most common mutation causing • Mutant Ras tumors are often cancer unresponsive to current treatments • Over 30% of all human cancers are driven by • Th
Slide 7: Is Ras is still the "undruggable target"?
Is Ras is still the “undruggable target”? Despite the importance of targeting Ras, no-one has had success. Why? • Many different types of Ras mutations • Ras protein is smooth with no obvious binding pockets • Mutated Ras is very similar to normal Ras • It occurs within the cell (not externally, whe
Slide 8: PTX-100 has a unique way of disrupting the Ras pathway
PTX-100 has a unique way of disrupting the Ras pathway Growth factor Cell • Targeting Ras directly has proven elusive Receptor membrane • PTX-100 disrupts the Ras pathway downstream of Ras (inhibits activation of Ras Ral, Rac & Rho) PTX-100 » “If you cannot inhibit the parent, inhibit the children”
Slide 9: PTX-100 addresses many different Ras mutations
PTX-100 addresses many different Ras mutations 3 types of Ras There are three Ras proteins (K, N & H) Each one has many different mutations that drive different cancers Competitor drugs are targeting one very specific type of Ras mutation » KRAS G12C PTX-100 has a unique mechanism we believe can add
Slide 10: Listed Ras peers
Listed Ras peers Drug AMG-510 MRTX849 G12Di PTX-100 K-Ras Inhibits KRAS G12C KRAS G12C KRAS G12D N-Ras RhoA Phase Phase 1 Phase 1 Preclinical Phase 1b Market US $121 B US$3 B A$24 M cap 10 GOOGLE FI NANCE 22 OCTOBER 2019
Slide 11: Market reacting to Ras developments
Market reacting to Ras developments • On the day of Amgen’s news announcement Mirati • Post release of ASCO data in June 2019, Amgen Therapeutics (NASDAQ: MRTX) also saw its shares open up (NASDAQ: AMGN) reached a peak price of US$ 211.90, 25%. appreciating by over 27%. • Further, its share price ap
Slide 12: PTX-100 trial underway
PTX-100 trial underway • Phase 1 trial in solid tumours previously completed – safety profile established • Phase 1b Basket PK/PD study underway in Australia “ » Myeloma » Lymphoma » Gastric cancer We know the pathway that is targeted by » Pancreatic cancer PTX-100 is critical to the survival of the
Slide 13: PTX-100 …not just Ras, but also the only drug targeting RhoA
PTX-100 …not just Ras, but also the only drug targeting RhoA • Given unmet need, it is possible only one pivotal trial post successful Phase 1b may be required » “Loxo-style” Basket heme and/or basket solid cancers enriched for RhoA & Ras mutations » Faster path to commercialisation » Small patient
Slide 14: Presentation summary
Presentation summary Only ASX exposure to Ras • PTX-100 uniquely positioned in hot Ras space • Potential advantages over competitors’ approaches • Trial commenced under leadership of Prof Miles Prince • Potential for shorter development path • Additional exposure to upside with PTX-200 • Funding in
Slide 15: Contact us
Contact us Steven Yatomi-Clarke CEO & Managing Director steven@ptxtherapeutics.com +61 417 601 440 ptxtherapeutics.com . 15 TAR G E TE D TH E R AP I E S Y I E L D I N G A D E E P C L I N I C AL P I P E L I N E
Prescient Therapeutics — AusBiotech Conference November 2019 on 6ix